You are here: Industry Insights > multiple sclerosis

News List

Multiple sclerosis trial focusing on people who can’t walk begins recruitment pharmatimes
November 20, 2020
A new trial focusing solely on multiple sclerosis patients who can’t walk is set to begin recruiting participants.
GW Pharma begins recruitment for US-based Sativex trial pharmatimes
November 06, 2020
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.
NICE recommends Novartis’ Mayzent on the heels of SMC approval pharmatimes
October 16, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium (SMC) approved the multiple sclerosis (MS) drug.
Glenmark Pharmaceuticals gets ANDA approval for multiple sclerosis drug expresspharma
October 10, 2020
Glenmark’s current portfolio consists of 164 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA.
Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis pharmaceutical-business-review
September 30, 2020
Anokion SA announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).
Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease pharmaceutical-business-review
June 01, 2020
Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
Charity launches online support services for self-isolators with MS pharmatimes
April 22, 2020
As of this morning – Wednesday April 22 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 129,044 with 17,337 deaths.
FDA and EMA agree to review shorter infusion time of Roche’s Ocrevus pharmaceutical-technology
April 22, 2020
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Roche’s applications for a shorter infusion time of Ocrevus to treat relapsing or primary progressive multiple sclerosis (MS).
SMC accepts four medicines for NHS use pharmatimes
April 15, 2020
Biogen’s Fampyra (fampridine) has become the first treatment funded by NHS Scotland to improve walking difficulties in adult patients with all types of multiple sclerosis (MS).
FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis europeanpharmaceuticalreview
March 31, 2020
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.

Previous page 1 2 3 4 5 6 Next page